A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS)

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509872-41-00

Acronym

ARGX-119-2302

Enrollment

Registered

2024-09-02

Start date

2024-09-24

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital neuromuscular disorders

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria, France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026